LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year
LIXTE Biotechnology filed its 2025 Annual Report highlighting leadership changes, expanded clinical trials for its lead cancer drug LB-100, successful capital raises, and the acquisition of Liora Technologies to enhance cancer treatment technologies. These developments position the company for growth in cancer therapeutics and med-tech innovation.